In summary, SGLT‐2 inhibitors (empagliflozing and canagliflozin) and GLP‐1 agonists (liraglutide, semaglutide) have been shown to improve CVOs in patients with T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.